RaySearch Laboratories AB (publ) (RAY-B.ST)
SEK 205.0
(1.49%)
SEK 205.0
(1.49%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 431.97 Million SEK | -13.1% |
| 2022 | 497.07 Million SEK | 1.23% |
| 2021 | 491.01 Million SEK | 812.87% |
| 2020 | 53.78 Million SEK | -37.31% |
| 2019 | 85.79 Million SEK | 1089.13% |
| 2018 | 7.21 Million SEK | -26.01% |
| 2017 | 9.75 Million SEK | -84.15% |
| 2016 | 61.52 Million SEK | 61.22% |
| 2015 | 38.16 Million SEK | -7.13% |
| 2014 | 41.09 Million SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| 2006 | - SEK | 0.0% |
| 2005 | - SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 879 Thousand SEK | -0.11% |
| 2024 Q1 | 880 Thousand SEK | 0.0% |
| 2023 Q2 | 465.63 Million SEK | -3.54% |
| 2023 Q4 | 431.97 Million SEK | -3.87% |
| 2023 Q3 | 449.35 Million SEK | -3.5% |
| 2023 FY | 431.97 Million SEK | -13.1% |
| 2023 Q1 | 482.72 Million SEK | -2.89% |
| 2022 FY | 497.07 Million SEK | 1.23% |
| 2022 Q3 | 478.52 Million SEK | -3.45% |
| 2022 Q4 | 497.07 Million SEK | 3.88% |
| 2022 Q1 | 486.36 Million SEK | -0.95% |
| 2022 Q2 | 495.62 Million SEK | 1.9% |
| 2021 Q4 | 491.01 Million SEK | 874.63% |
| 2021 Q2 | 51.69 Million SEK | -5.03% |
| 2021 Q3 | 50.38 Million SEK | -2.55% |
| 2021 Q1 | 54.43 Million SEK | 1.2% |
| 2021 FY | 491.01 Million SEK | 812.87% |
| 2020 FY | 53.78 Million SEK | -37.31% |
| 2020 Q2 | 77.28 Million SEK | -12.23% |
| 2020 Q3 | 66.01 Million SEK | -14.58% |
| 2020 Q4 | 53.78 Million SEK | -18.52% |
| 2020 Q1 | 88.05 Million SEK | 2.63% |
| 2019 FY | 85.79 Million SEK | 1089.13% |
| 2019 Q1 | 140.48 Million SEK | 1847.05% |
| 2019 Q2 | 123.8 Million SEK | -11.87% |
| 2019 Q3 | 99.08 Million SEK | -19.96% |
| 2019 Q4 | 85.79 Million SEK | -13.41% |
| 2018 Q2 | 8.66 Million SEK | -4.12% |
| 2018 Q4 | 7.21 Million SEK | -9.17% |
| 2018 FY | 7.21 Million SEK | -26.01% |
| 2018 Q1 | 9.03 Million SEK | -7.32% |
| 2018 Q3 | 7.94 Million SEK | -8.33% |
| 2017 Q3 | 10.59 Million SEK | 1.0% |
| 2017 Q2 | 10.49 Million SEK | -79.65% |
| 2017 Q4 | 9.75 Million SEK | -7.97% |
| 2017 Q1 | 51.56 Million SEK | -16.19% |
| 2017 FY | 9.75 Million SEK | -84.15% |
| 2016 FY | 61.52 Million SEK | 61.22% |
| 2016 Q2 | 36.12 Million SEK | -2.75% |
| 2016 Q1 | 37.15 Million SEK | -2.65% |
| 2016 Q4 | 61.52 Million SEK | 32.23% |
| 2016 Q3 | 46.53 Million SEK | 28.79% |
| 2015 FY | 38.16 Million SEK | -7.13% |
| 2015 Q4 | 38.16 Million SEK | -27.16% |
| 2015 Q2 | 53.08 Million SEK | 10.41% |
| 2015 Q1 | 48.08 Million SEK | 16.99% |
| 2015 Q3 | 52.39 Million SEK | -1.31% |
| 2014 FY | 41.09 Million SEK | 0.0% |
| 2014 Q3 | 24.92 Million SEK | 8.13% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q2 | 23.05 Million SEK | 0.0% |
| 2014 Q4 | 41.09 Million SEK | 64.89% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2009 Q4 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| 2006 FY | - SEK | 0.0% |
| 2005 FY | - SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aino Health AB (publ) | 164 Thousand SEK | -263300.61% |
| Bonzun AB (publ) | 554 Thousand SEK | -77874.188% |
| Kontigo Care AB (publ) | 3.67 Million SEK | -11654.476% |
| Medhelp Care Aktiebolag (publ) | - SEK | -Infinity% |
| Surgical Science Sweden AB (publ) | 40.02 Million SEK | -979.322% |